NSI-189 Phosphate Health Nootropic Supplements CAS 1270138-40-3

NSI-189 Phosphate Health Nootropic Supplements CAS 1270138-40-3

NSI-189 Background

NSI-189 is a benzylphiperizine-aminiopyridine, nootropic and neurogenic research chemical created by Neuralstem, Inc. that was derived from pyrazine and nicotinamide. Studies have shown that it stimulates neurogenesis of human hippocampus-derived neural stem cells in vivo and vitro .

In healthy adult mice, NSI-189 has been shown to increase the hippocampal volume by 20% and reverse behavioral symptoms in mouse depression models, meaning at the source it could address depression . The hippocampus is responsible for spatial navigation, along with the consolidation of information from short-term memory to long-term memory.

Basic Information

NSI-189 Benefits

Tests have shown that NSI-189 significantly improved behavioral responses that are associated with depression . In humans it may counter hippocampal atrophy which is seen in disorders such as MDD, reversing their symptoms. A phase 1B randomized, double-blind, placebo-controlled, multiple-dose escalation study conducted over a 28 day period showed behavioral efficacy in 24 patients who were orally administered NSI-189 .

Dosing NSI-189

Phase 1A tested escalating doses of the neurogenic compound NSI-189 in healthy patients, 1B tested the safety of escalating doses in 24 depressed patients over the course of 28 days . During phase 1B patients were administered 40 mg per day, and 80 mg per day, and at the highest dose 120 mg per day. No serious adverse events occurred during the time of the study and the drug was well tolerated. Reduction in cognitive and depressive symptoms were observed across all measures for the two lower doses 40 mg/day and 80 mg/day but not for the highest dose 120 mg/day .

Other information

The main limitations of the phase 1B study was the small sample size of each cohort, and also the fact that efficacy analyses were not the primary focus. In summary, NSI-189 looks promising as a potential treatment for MDD in a Phase 1B, double-blind, randomized, placebo-controlled, multiple-dose study with three ascending cohorts.

The preliminary findings are supportive of the view that neurogenesis-based platforms are capable of identifying auspicious new treatments for MDD. However, further studies are imperative to confirm the preliminary observations. Neuralstem intends to pursue further clinical trials for various encephalopathic conditions including post-traumatic stress disorder, traumatic brain injury, and natural aging.

FAQ

Q1: Are you a manufacturer ?

A: Yes, We manufacture bulk products in our factory located in Jiayu, Hubei, and produce small quantity and customer synthesis products in our lab located in Wuhan. But we also do some trading business.

Q2: What`s your delivery

A: We send goods in 3 working day after receiving your payment by DHL, FEDEX, TNT, EMS, AIR OR SEA as you request, usually you can find shipping details in 3 to 5 working days after your payment.

Q3: What certificates and documents do you offer?

A: Some technical paperwork is available, such as COA, HNMR, HPLC, LC-MS etc.

Wuhan Vanz Pharm Inc. was founded in 2011, originally located in High-Tech Industrial Park of Wuhan Economic and Technological Development Zone and moved to Panhu Industrial Park in Jiayu County, Hubei Province in 2015. Registered capital is RMB 12 million (1 million for trading company and 11 million for affiliated company). We are comprehensive enterprise with business range covering R&D, production and sales of APIs, pharmaceutical intermediates, plant extracts, all kinds of organic intermediates and so on. We bought 14,000 square meters production base in Panhu Industrial Park, established several pharmaceutical synthesis production lines, and continually expands our production capacity.

Our products are widely used in the industries of pharmaceuticals, veterinary drugs, pesticides, electronics, cosmetics, health product, food, and so on, which win high popularity among customers and share extensive markets both domestic and abroad. We have customers in more than 100 countries and regions, including the United States, Europe, Japan, Korea, Russia and so on.

Our technical team in R&D center consists of professors, senior engineers, members with Doctor, Master and Bachelor's Degrees. We follow and develop the nationally leading technology products aimed at environmental protection. With our joint efforts, Vanz Pharm is already a key enterprise in chemical pharmaceutical industry in China. Some of our products rank No.1 of sales in 2015.

Vanz Pharm employs full sets of advanced equipment of production and testing to ensure the high quality of product. Every single product must pass strict quality control test and inspection and meet the high national standards or in-house standards.

We are ISO9001 certified enterprise, registered China Famous Trademark, won innovation funds support from Wuhan government, and obtained several invention patents. We are approved as the most reliable supplier in the industry by our customers for consecutive six years.

Our aim is "persistently improving, to satisfy customer's incessant pursuit". Every staff member of Vanz Pharm will keep this in mind all the time, and enforce it at every detail of operation and management of the company. All honors belong to the past, Vanz people will do their best to develop and produce more perfect product and contribute to the chemical pharmaceutical industries worldwide.